Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: The Casale Monferrato Study

Diabetic Medicine

Volumn 21, Issue 8, 2004, Pages 823-828

  Bruno, G ^a   Giunti, S ^a   Bargero, G ^b   Ferrero, S ^a   Pagano, G ^a   Cavallo Perin, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Ospedale S Spirito Casale Monferrato   (Italy)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Hypertension; Left ventricular hypertrophy

Indexed keywords

CREATININE; FIBRINOGEN; HEMOGLOBIN A1C; URIC ACID;

ADULT; AGE; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; QT DISPERSION; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADULT; AGED; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ITALY; MALE; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; SEX DISTRIBUTION;

EID: 3843134187     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01246.x     Document Type: Article

References (32)

1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-41.
2. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q et al. Reduction of cardiovascular risk by regression of echocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-21.
3. Nielsen FS, Sato A, Ali S, Tarnow L, Smidt UM, Kastrup J et al. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive normoalbuminuric NIDDM patients. Diabetes Care 1998; 21: 804-809.
4. Lorell BH, Carabello BA. Left ventricular hypertrophy. Pathogenesis, detection, and prognosis. Circulation 2000; 102: 470-479.
5. Lind L, Andersson PE, Andren B, Hanni A, Lithel HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13: 433-438.
6. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100: 1802-1807.
7. Bruno G, Cavallo-Perin P, Bargero G, Borra M, Calvi V, D'Errico N et al. Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of non-insulin-dependent diabetic subjects. Diabetes Care 1996; 19: 43-47.
8. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. The associations of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes. Ann Intern Med 1996; 125: 653-657.
9. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Glycaemic control and cardiovascular risk factors in Type 2 (non-insulin- dependent) diabetes: a population-based study. Diabetic Med 1998; 15: 304-307.
10. Bruno G, LaPorte R, Merletti F, Biggeri A, McCarty D, Pagano G. National diabetes programmes: application of capture-recapture to 'count' diabetes? Diabetes Care 1994; 17: 548-556.
11. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2003; 26: 2150-5.
12. Veglio M, Bruno G, Borra M, Macchia G, Bargero G, D'Errico N et al. Prevalence of increased QT interval duration and dispersion in Type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med 2002; 251: 317-324.
13. Okin PM, Devereux RB, Jerb S, Julius S, Kjeldsen SE. Dahlöf and the LIFE Study Investigators. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am J Hypertens 2001; 14: 775-782.
14. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992; 20: 1180-1186.
15. Casale PN, Devereux RB, Alonso DR, Campo E, Ligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer electrocardiogram interpretation: necropsy validation. Circulation 1987; 75: 565-572.
16. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140: 848-856.
17. De Bacquer D, De Bacquer G, Kornitzer M. Prevalences of ECG findings in a large population based samples of men and women. Heart 2000; 84: 625-633.
18. Sutherland SE, Gazes PC, Keil JE, Gilbert GE, Knapp RG. Electrocardiographic abnormalities and 30-year mortality among white and black men of the Charleston Heart Study. Circulation 1993; 88: 2685-2692.
19. Knutsen R, Knutsen SF, Curb JD, Reed DM, Kautz JA, Yano K. The predictive value of resting electrocardiograms for 12-year incidence of coronary heart disease in the Honolulu Heart Program. J Clin Epidemiol 1988; 41: 293-302.
20. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE et al. Trends in the prevalence of hypertension, anti-hypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Medical 1999; 340: 1221-1227.
21. Dunn FG, McLenachan J, Isles CG, Brown I, Dargie HJ, Lever AF et al. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood Pressure Clinic. J Hypertens 1990; 8: 775-82.
22. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am J Cardiol 1991; 68: 85-89.
23. Griffin M, Lee HW, Zhao L, Eghbali-Webb M. Gender-related differences in proliferative response of cardiac fibroblast to hypoxia: effects of estrogen. Mol Cell Biochem 2000; 215: 21-30.
24. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 2000; 106: 589-97.
25. Riemer RK, Wu YY, Bottari SP, Jacobs MM, Goldfien A, Roberts JM. Estrogen reduces β-adrenoceptor-mediated cAMP production and the concentration of the guanyl nucleotide-regulatory protein, Gs, in rabbit myometrium. Mol Pharmacol 1988; 33: 389-95.
26. Palmieri V, Celentano A, Roman MJ, De Simone G, Lewis MR, Best L et al. Fibrinogen and preclinical echocardiographic target organ damage. The Strong Heart Study. Hypertension 2001; 38: 1068-74.
27. Lip GYH, Blann AD, Jones AF, Lip BL, Beevers DG. Relation of endothelium, thrombogenesis and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566-71.
28. Nielsen FS, Ali S, Rossing P, Bang LE, Svendsen TL, Gall MA et al. Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. Diabetic Med 1997; 14: 538-546.
29. Suzuki K, Kato K, Hanyu O, Nakagawa O, Aizawa Y. Left ventricular mass index increases in proportion to the progression of diabetic nephropathy in Type 2 diabetic patients. Diabetes Res Clin Pract 2001; 54: 173-180.
30. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B et al. Urine albumine/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143: 319-326.
31. Sundström J, Lind L, Ärnlöv J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001; 103: 2346-2351.
32. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-90.